SLINDA

This brand name is authorized in Ecuador, Finland, France, Poland, Spain.

Active ingredients

The drug SLINDA contains one active pharmaceutical ingredient (API):

1
UNII N295J34A25 - DROSPIRENONE
 

Drospirenone is a progestogen. In a therapeutic dosage, drospirenone also possesses antiandrogenic and mild antimineralocorticoid properties. It has no estrogenic, glucocorticoid and antiglucocorticoid activity. This gives drospirenone a pharmacological profile closely resembling the natural hormone progesterone.
 
Read more about Drospirenone

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
G03AC10 G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03A Hormonal contraceptives for systemic use → G03AC Progestogens
Discover more medicines within G03AC10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria 5915-MEE-0221
ES Centro de información online de medicamentos de la AEMPS 84603
FI Lääkealan turvallisuus- ja kehittämiskeskus 061682, 442936
FR Base de données publique des médicaments 68971188
PL Rejestru Produktów Leczniczych 100410232

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈